Navigation Links
Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
Date:5/1/2008

SAN DIEGO, May 1 /PRNewswire-FirstCall/ -- Favrille, Inc. (Nasdaq: FVRL), a biopharmaceutical company developing patient-specific, active immunotherapies for the treatment of cancer, announced today that it will host a conference call and live webcast at 5:00 p.m. Eastern Time on Thursday, May 8, 2008 to discuss the Company's first quarter 2008 financial results. A press release will be issued after the U.S. stock markets close that day.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO)

A live audio webcast of management's presentation will be available on the Investor Relations section of the Company's web site at http://www.favrille.com. Alternatively, callers may participate in the conference call by dialing (888) 713-4205 or (617) 213-4862, passcode 61931952. To pre-register for this call, please go to https://www.theconferencingservice.com/prereg/key.process?key=PFYXYBR33. Callers who pre-register will be given a unique PIN to gain immediate access to the call and bypass the live operator. You may pre-register at any time, including up to and after the call start time. A telephone replay of the call will also be available for 48 hours. The telephone replay can be accessed by dialing (888) 286-8010 or (617) 801-6888, passcode 61738291.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, Specifid(TM) (formerly FavId(R)), is based upon unique genetic information extracted from a patient's tumor. Specifid is currently under investigation in a Phase 3 registration trial for patients with fol
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
2. Favrille Announces $21.1 Million Registered Direct Offering
3. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
4. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
5. Favrille to Present at BIO InvestorForum
6. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
7. Favrille CEO to Present at Bear Stearns Healthcare Conference
8. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
9. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
10. Gen-Probe to Webcast Presentation at Deutsche Bank 33rd Annual Health Care Conference
11. InterMune to Present at Deutsche Bank Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)...  Having the right people at the table for ... growth and achieving clinical and operational goals. The 22 ... July 20-22, 2014, in San Diego ... healthcare experts discussing how partnerships have positively impacted their ... Chief Executive Officer of Cape Regional Medical Center located ...
(Date:7/23/2014)... La Jolla, CA (PRWEB) July 23, 2014 ... adipose stem cell therapy in the US aimed at ... today announced their newest clinical study for Parkinson’s disease. ... and efficacy of stem cell therapy are paramount when ... , This clinical study makes stem cell therapy accessible ...
(Date:7/23/2014)... July 23, 2014 DuPont Pioneer announced ... as vice president of Agricultural Biotechnology (ABT), effective July ... he served most recently as president, chief executive officer ... business leadership in the seed and crop protection industry ... Paul E. Schickler , president of DuPont Pioneer. “I ...
(Date:7/23/2014)... regulated information -- UCB today announced an ... with positive topline results from the latest Phase ... designed to evaluate the efficacy and safety of ... titration) compared to placebo, as adjunctive treatment in ... fully controlled despite treatment with one or two ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
... Pharma AG today,announced that the US Food and ... (IND) application submitted by Nitec for the,initiation of ... results of a European Phase III trial (CAPRA-1;,Circadian ... dossier for marketing authorization in Europe. The FDA,s,acceptance ...
... and advantageous for the U.S. Army,s Chemical Materials Agency ... waste during regular chemical agent disposal operations, says a ... committee that wrote the report also determined that the ... the submission of data from previous trial burns -- ...
... Pacific Northwest National Laboratory,have discovered a way to ... creation of a portable biosensor that can address ... nerve agents, the need to quickly distinguish between ... , The sensor components resemble a pregnancy test ...
Cached Biology Technology:Nitec's IND Application for Clinical Development With Lodotra Accepted by the FDA 2Nitec's IND Application for Clinical Development With Lodotra Accepted by the FDA 3Report recommends off-site disposal of secondary waste 2Report recommends off-site disposal of secondary waste 3Report recommends off-site disposal of secondary waste 4Truly sick or simply scared? 2
(Date:7/23/2014)... Chrysomya megacephala is commonly found in dead ... the time of death, referred to as the post ... C. megacephala from Tamil Nadu is provided ... molecular characterization through generation of DNA barcoding. This study, ... access Biodiversity Data Journal . , Chrysomya ...
(Date:7/23/2014)... struggle to deal with ever-growing piles of electronic waste ... just how much there is and where it really ... Science & Technology , their study found that nearly ... into just seven developing countries with major potential ... Knut Breivik and colleagues note that the export from ...
(Date:7/23/2014)... sulfur-oxidizing bacterial group called SUP05 will play an increasingly ... world,s oceans as oxygen minimum zones expand, according to ... the National Academy of Sciences . , University of ... anoxic fjord, Canada,s Saanich Inlet, to chart how microbial ... "Our study paints a very detailed picture of how ...
Breaking Biology News(10 mins):Dead body feeding larvae useful in forensic investigations 2Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... Connie Hedegaard, the EU commissioner for Climate Action, ... new Nordic centre for Europe,s main climate innovation ... entrepreneurs, businesses, climate professionals, students and government officials ... European partnership to work on innovative solutions for ...
... and technology (S&T) eroded further during the last decade, ... their innovation capacities. According to a report released today ... body of the National Science Foundation (NSF) and an ... economies, taken together, now perform a larger share of ...
... D.C., February 6, 2014Dietary supplement users take these ... effort to develop a healthier lifestyle, according to ... , a peer-reviewed scientific publication. The review, "Health ... Nutrition Journal .2014, 13:14), co-authored by Council for ...
Cached Biology News:European Union launches Nordic climate innovation center 2European Union launches Nordic climate innovation center 3US lead in science and technology shrinking 2US lead in science and technology shrinking 3US lead in science and technology shrinking 4Scientific review points to supplement users engaging in a pattern of healthy habits 2
... microPET R4 is the lowest priced, full ... the world. Despite the microPET R4 ... systems in all performance categories; count rate ... set., microPET is a dedicated small animal ...
... to significantly increase the shelf life of ... increased at room temperature storage conditions in ... is subjected to 0.45 micron filtration, and ... formulation insures consistently high levels of activity ...
... 220 utilizes utilizies CTI Molecular Imaging's ... superior resolution, sensitivty, and a large ... the flexibility to image multiple mice ... microPET is a dedicated small animal ...
... This product has been developed to significantly ... labeled proteins. Stability is increased at ... 2-8 centigrade. This product is subjected ... mercury or azide. This formulation insures ...
Biology Products: